08:57 AM EDT, 10/10/2024 (MT Newswires) -- Kezar Life Sciences ( KZR ) said Thursday it has received an unsolicited, non-binding takeover proposal from Concentra Biosciences for a cash consideration of $1.10 per share and is evaluating the offer.

The proposal includes a contingent value right to receive 80% of any net proceeds from Kezar's development programs or intellectual property, Kezar said.

Kezar shares were up 4% in recent Thursday premarket activity.

Price: 0.9089, Change: +0.04, Percent Change: +5.16